Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ADPT - Adaptive Biotechnologies Corpor
Market Cap 1.15B P/E - EPS this Y 16.70% Ern Qtrly Grth -
Income -225.25M Forward P/E -7.88 EPS next Y 20.00% 50D Avg Chg 8.00%
Sales 170.28M PEG -0.09 EPS past 5Y - 200D Avg Chg -
Dividend N/A Price/Book 2.91 EPS next 5Y 21.60% 52W High Chg -40.00%
Recommedations 2.00 Quick Ratio 4.38 Shares Outstanding 145.09M 52W Low Chg 34.00%
Insider Own 2.83% ROA -16.60% Shares Float 96.82M Beta 1.24
Inst Own 97.61% ROE -58.34% Shares Shorted/Prior 9.10M/8.77M Price 7.96
Gross Margin 43.61% Profit Margin -132.29% Avg. Volume 1,029,233 Target Price 6.40
Oper. Margin -99.68% Earnings Date May 7 Volume 845,935 Change -3.52%
Healthcare | Biotechnology | United States
About Adaptive Biotechnologies Corpor

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corpor News
04/17/24 Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
04/02/24 Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
03/27/24 The 7 Best Penny Stocks to Buy in Q2 2024
03/27/24 Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
03/10/24 Team behind popular Falcon AI models unveils new startup with $20 million in funding aimed at helping companies tailor LLMs for business
02/22/24 Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
02/15/24 Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2023 Earnings Call Transcript
02/15/24 Q4 2023 Adaptive Biotechnologies Corp Earnings Call
02/14/24 Adaptive Biotechnologies Corp (ADPT) Faces Revenue Decline Amid Growth in MRD Segment
02/14/24 Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
02/13/24 Here’s Why Adaptive Biotechnologies Corporation (ADPT) Declined in Q4
02/12/24 Exploring Analyst Estimates for Adaptive Biotechnologies (ADPT) Q4 Earnings, Beyond Revenue and EPS
01/29/24 Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
12/27/23 Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/12/23 Cathie Wood Is Loading Up on These 3 Small-Cap Stocks: Should You?
12/11/23 16 Best Penny Stocks To Buy For 2024
12/09/23 Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
12/05/23 Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
11/17/23 Analysts Just Slashed Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) EPS Numbers
11/10/23 Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript
ADPT Chatroom

User Image Beestings6969 Posted - 3 hours ago

@AnchorsAweigh accumulating $ADPT at these levels for BOOM eventually ✅👌🏼

User Image MLinv Posted - 11 hours ago

$ADPT Next limit buy executed at 2.34 averaged down from 3.18 to 2.83 avg. ST in B possibly in this range. Let’s see. $ARKG

User Image Stock_Titan Posted - 1 day ago

$ADPT Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024 https://www.stocktitan.net/news/ADPT/adaptive-biotechnologies-to-report-first-quarter-2024-financial-4tfls9b7wd89.html

User Image ___King_Chaz___ Posted - 1 day ago

$ADPT lower lows....lower highs....🥱

User Image Noobnioo Posted - 1 day ago

$ADPT You still have 20 minutes and you can buy it at the best price.

User Image Noobnioo Posted - 1 day ago

$ADPT buy zone

User Image ___King_Chaz___ Posted - 2 days ago

$ADPT walking it down....same pattern for many months now....🥱

User Image jster Posted - 3 days ago

$ADPT in at 3.08 for a quick swing

User Image Tradingbop Posted - 3 days ago

$ADPT swingtrade

User Image Tradingbop Posted - 3 days ago

$ADPT daily bop 3.10 breakout.

User Image Tradingbop Posted - 3 days ago

$ADPT long🚀

User Image Stocksrunner Posted - 6 days ago

As the trading week comes to a close, we saw several companies stage impressive rallies from their opening prices to end the day much higher. Here's a rundown of the top performers: $YYAI - Opened at $1.02 and closed at $1.50, a remarkable 47.06% surge. $CNEY - Climbed from an opening of $0.99 to a closing price of $1.16, a 17.17% gain. $ADPT - Saw a 16.22% increase, rising from $2.59 at the open to $3.01 at the close. $URGN - Jumped 15.36% on the day, starting at $13.09 and finishing at $15.10. $XFOR - Ended 10.74% higher than its $1.21 open, closing at $1.34. Keep an eye on these movers for potential opportunities in the market! 📈💼

User Image ___King_Chaz___ Posted - 6 days ago

$ADPT lower highs....lower lows....still in hard downtrend....I feel confident 2.20 and below will show in the coming weeks.....

User Image iLoveSqueezePlays Posted - 6 days ago

$ADPT my 5 dollar call gonna print

User Image _www_larval_com_ Posted - 6 days ago

$ADPT just shot 3% higher to 14% (~1Mv) a moment ago, 04/19 options, follow for more volatility.

User Image ___King_Chaz___ Posted - 1 week ago

$ADPT here we go....new 52 week low....no volume....let's see how low they take it.....im ready to buy in when it reaches 2.20 and below!

User Image ___King_Chaz___ Posted - 1 week ago

$ADPT 2.20 🎯

User Image Bigeyes2 Posted - 1 week ago

$ADPT Swing-Long

User Image jaydilks Posted - 1 week ago

$ARKG leaders today. $ADPT $PRME $GH

User Image asiantrick Posted - 1 week ago

$ADPT garbage

User Image ___King_Chaz___ Posted - 1 week ago

$ADPT 2.20 🎯

User Image DonCorleone77 Posted - 2 weeks ago

$ADPT Adaptive Biotechnologies sees Q1 revenue $41M-$43M, consensus $38.2M

User Image ___King_Chaz___ Posted - 2 weeks ago

$ADPT big selling volume today........deeper drop on the way in coming days......bearish short term....

User Image RocketThief Posted - 2 weeks ago

$ADPT don’t love the strat review outcome here but a valuation-based swing seems in order

User Image Peterson28 Posted - 2 weeks ago

$ADPT No BO near term. Focus on the fundamental which is decent tho not great. But current valuation priced in almost no growth. Relatively undervalued. Adding here.

User Image ___King_Chaz___ Posted - 2 weeks ago

$ADPT 2.20 by the end of the month 🧐

User Image JojoNYC Posted - 2 weeks ago

$ADPT little movement , despite restructuring

User Image Stock_Titan Posted - 2 weeks ago

$ADPT Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue https://www.stocktitan.net/news/ADPT/adaptive-biotechnologies-provides-strategic-review-update-and-oxsbmdbj4qo3.html

User Image ___King_Chaz___ Posted - 2 weeks ago

$ADPT 2.2-2.4 🎯👀

User Image iLoveSqueezePlays Posted - 2 weeks ago

$ADPT grabbed some 5 dollar calls for next month. Seems undervalued

Analyst Ratings
BTIG Buy Apr 4, 24
Goldman Sachs Neutral Feb 16, 24
JP Morgan Overweight Feb 15, 24
Piper Sandler Overweight Nov 13, 23
Morgan Stanley Equal-Weight Oct 24, 23
Piper Sandler Overweight Oct 16, 23
Piper Sandler Overweight Aug 8, 23
Morgan Stanley Equal-Weight Aug 4, 23
Morgan Stanley Equal-Weight May 5, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PETERSON TYCHO Chief Financial Offi.. Chief Financial Officer Jun 20 Sell 8.14 134,961 1,098,583 399,219 06/21/23
PETERSON TYCHO Chief Financial Offi.. Chief Financial Officer Jun 20 Option 7.3 134,961 985,215 534,180 06/21/23
PETERSON TYCHO Chief Financial Offi.. Chief Financial Officer Jun 15 Sell 8.53 70,000 597,100 399,219 06/20/23
PETERSON TYCHO Chief Financial Offi.. Chief Financial Officer Jun 15 Option 7.3 14,328 104,594 413,547 06/20/23
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Apr 10 Sell 8.57 3,125 26,781 175,361 04/12/23
GRIFFIN MICHELLE RENEE Director Director Mar 27 Sell 8.4913 2,341 19,878 20,627 03/29/23
PISKEL KYLE Principal Accounting.. Principal Accounting Officer Mar 06 Sell 8.58 3,529 30,279 87,564 03/08/23
LO FRANCIS Chief People Officer Chief People Officer Mar 06 Sell 8.57 6,816 58,413 168,469 03/08/23
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Mar 06 Sell 8.59 18,878 162,162 139,678 03/08/23
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Mar 06 Sell 8.59 23,684 203,446 178,486 03/08/23
BENZENO SHARON Chief Commercial Ofc.. Chief Commercial Ofc Imm Med Mar 06 Sell 8.57 11,749 100,689 223,826 03/08/23
SOOD NITIN Chief Commercial Off.. Chief Commercial Officer, MRD Mar 06 Sell 8.59 16,474 141,512 231,010 03/08/23
RUBINSTEIN JULIE President President Mar 06 Sell 8.57 22,668 194,265 336,824 03/08/23
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Jan 09 Sell 8.54 3,125 26,687 113,518 01/11/23
PISKEL KYLE Principal Accounting.. Principal Accounting Officer Nov 16 Sell 8.87 959 8,506 46,706 11/17/22
SOOD NITIN Chief Commercial Off.. Chief Commercial Officer, MRD Nov 01 Sell 8.00 31,066 248,528 114,505 11/01/22
SOOD NITIN Chief Commercial Off.. Chief Commercial Officer, MRD Aug 05 Sell 10.98 17,540 192,589 145,571 08/05/22
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Jul 07 Sell 10 3,125 31,250 119,768 07/08/22
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Apr 07 Sell 13.17 831 10,944 122,893 04/08/22
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Mar 08 Sell 11.44 2,387 27,307 72,859 03/10/22
BALDO LANCE Chief Medical Office.. Chief Medical Officer Mar 08 Sell 11.43 3,350 38,290 17,171 03/10/22
LO FRANCIS Chief People Officer Chief People Officer Mar 08 Sell 11.44 3,582 40,978 89,588 03/10/22
ROBINS CHAD M CEO and Chairman CEO and Chairman Mar 07 Option 6.32 44,445 280,892 1,930,969 03/09/22
ROBINS CHAD M CEO and Chairman CEO and Chairman Mar 07 Sell 11.9 44,445 528,896 1,916,154 03/09/22
BALDO LANCE Chief Medical Office.. Chief Medical Officer Mar 07 Sell 12.01 2,373 28,500 20,521 03/08/22
RUBINSTEIN JULIE President President Mar 04 Sell 12.01 4,613 55,402 226,513 03/08/22
BENZENO SHARON Chief Business Devel.. Chief Business Development Off Mar 04 Sell 12.01 2,670 32,067 102,596 03/08/22
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Mar 04 Sell 12.01 1,569 18,844 75,246 03/08/22
PISKEL KYLE Principal Accounting.. Principal Accounting Officer Mar 04 Sell 12.01 220 2,642 47,665 03/08/22
LO FRANCIS Chief People Officer Chief People Officer Mar 04 Sell 12.01 1,569 18,844 93,170 03/08/22
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Mar 04 Sell 12.01 4,517 54,249 311,960 03/08/22
ROBINS CHAD M CEO and Chairman CEO and Chairman Mar 04 Sell 12.01 4,424 53,132 1,916,154 03/08/22
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Mar 04 Sell 12.01 1,244 14,940 123,724 03/08/22
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Jan 07 Sell 23.32 1,021 23,810 50,833 01/10/22
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Dec 22 Option 7.18 15,338 110,127 30,374 12/23/21
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Dec 22 Sell 30 15,338 460,140 15,036 12/23/21
Cohen Chad M Chief Financial Offi.. Chief Financial Officer Dec 22 Sell 30 10,000 300,000 21,604 12/23/21
Cohen Chad M Chief Financial Offi.. Chief Financial Officer Dec 22 Option 7.27 10,000 72,700 31,604 12/23/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Oct 19 Option 6.55 11,200 73,360 73,060 10/21/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Oct 19 Sell 33.53 11,200 375,536 69,360 10/21/21
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Oct 07 Sell 33.07 3,125 103,344 51,854 10/08/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Oct 06 Option 6.32 11,685 73,849 73,255 10/08/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Oct 06 Sell 32.85 11,685 383,852 69,360 10/08/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Sep 15 Sell 37.15 11,685 434,098 69,360 09/15/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Sep 15 Option 6.32 11,685 73,849 73,255 09/15/21
ROBINS CHAD M CEO and Chairman CEO and Chairman Sep 10 Sell 38.67 43,499 1,682,106 1,673,461 09/10/21
Cohen Chad M Chief Financial Offi.. Chief Financial Officer Sep 09 Sell 39.36 14,375 565,800 21,604 09/09/21
Cohen Chad M Chief Financial Offi.. Chief Financial Officer Sep 09 Option 6.91 14,375 99,331 26,604 09/09/21
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Sep 09 Sell 40 495 19,800 15,036 09/09/21
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Sep 09 Option 6.55 495 3,242 15,531 09/09/21